The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMDS 2026 | Current best practices and emerging treatment strategies in higher-risk MDS
In this roundtable discussion, Yazan Madanat, MD, UT Southwestern Medical Center, Dallas, TX, Maximilian Stahl, MD, Yale Cancer Center, New Haven, CT, and Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discuss current best practices and emerging treatments for higher-risk myelodysplastic syndromes (MDS). Dr Madanat highlights targeted therapies, including ivosidenib and the Phase III PyramIDH trial (NCT06465953), while Dr Stahl discusses lessons from unsuccessful clinical trials and Dr Zeidan explores emerging monoclonal antibodies. The experts also examine the implications of the Phase III VERONA trial (NCT04401748) and the role of transplantation, including findings from the PALOMA trial (NCT04061239). This roundtable discussion took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
